sgal 9 (Galectin Therapeutics)
86
Structured Review
Galectin Therapeutics
sgal 9
Sgal 9, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sgal-9/9+sgal/10__3390_slash_biomedicines14030647-44-56-57
Average 86 stars, based on 1 article reviews
Sgal 9, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sgal-9/9+sgal/10__3390_slash_biomedicines14030647-44-56-57
Average 86 stars, based on 1 article reviews
sgal 9 - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Infection:Article Title: Role of co‑inhibitory molecules in the treatment of psoriasis (Review) Article Snippet: Author, year Name Type Targeting Status Efficacy Adverse event (Refs.) Abrams et al , 1999 Mease et al , 2017 Mease et al , 2011 Strand et al , 2018 Abatacept Fusion protein CD80/CD86 Phase III Modest impact on psoriasis lesions while beneficial trends overall in PsA Increased risk of infection, transient headache ( 23 , 27 , 62 , 63 ) Kim et al , 2016 Peng et al , 2020 Imai et al , 2015 PD-L1-Fc Fusion protein PD-1 Preclinical Alleviated psoriatic inflammation and exhibit additive effects with or without other biologics / ( 43 , 45 , 64 ) Ellis et al , 2021 GSK2831781 mAb LAG-3 Phase I LAG-3 + and CD3 + T-cell counts reduced in peripheral blood and biopsies, reduced pro-inflammatory genes expression, disease activity improved up Headache, nasopharyngitis, back pain ( 56 ) Niwa et al , 2009 sGal-9 Stable form of Article Title: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Article Snippet: 1521-6616/$ see front matter © 200 doi:10.1016/j.clim.2009.04.012 Expressing:Article Title: Role of co‑inhibitory molecules in the treatment of psoriasis (Review) Article Snippet: Author, year Name Type Targeting Status Efficacy Adverse event (Refs.) Abrams et al , 1999 Mease et al , 2017 Mease et al , 2011 Strand et al , 2018 Abatacept Fusion protein CD80/CD86 Phase III Modest impact on psoriasis lesions while beneficial trends overall in PsA Increased risk of infection, transient headache ( 23 , 27 , 62 , 63 ) Kim et al , 2016 Peng et al , 2020 Imai et al , 2015 PD-L1-Fc Fusion protein PD-1 Preclinical Alleviated psoriatic inflammation and exhibit additive effects with or without other biologics / ( 43 , 45 , 64 ) Ellis et al , 2021 GSK2831781 mAb LAG-3 Phase I LAG-3 + and CD3 + T-cell counts reduced in peripheral blood and biopsies, reduced pro-inflammatory genes expression, disease activity improved up Headache, nasopharyngitis, back pain ( 56 ) Niwa et al , 2009 sGal-9 Stable form of Article Title: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Article Snippet: 1521-6616/$ see front matter © 200 doi:10.1016/j.clim.2009.04.012 Activity Assay:Article Title: Role of co‑inhibitory molecules in the treatment of psoriasis (Review) Article Snippet: Author, year Name Type Targeting Status Efficacy Adverse event (Refs.) Abrams et al , 1999 Mease et al , 2017 Mease et al , 2011 Strand et al , 2018 Abatacept Fusion protein CD80/CD86 Phase III Modest impact on psoriasis lesions while beneficial trends overall in PsA Increased risk of infection, transient headache ( 23 , 27 , 62 , 63 ) Kim et al , 2016 Peng et al , 2020 Imai et al , 2015 PD-L1-Fc Fusion protein PD-1 Preclinical Alleviated psoriatic inflammation and exhibit additive effects with or without other biologics / ( 43 , 45 , 64 ) Ellis et al , 2021 GSK2831781 mAb LAG-3 Phase I LAG-3 + and CD3 + T-cell counts reduced in peripheral blood and biopsies, reduced pro-inflammatory genes expression, disease activity improved up Headache, nasopharyngitis, back pain ( 56 ) Niwa et al , 2009 sGal-9 Stable form of Article Title: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Article Snippet: 1521-6616/$ see front matter © 200 doi:10.1016/j.clim.2009.04.012 Incubation:Article Title: Role of co‑inhibitory molecules in the treatment of psoriasis (Review) Article Snippet: Author, year Name Type Targeting Status Efficacy Adverse event (Refs.) Abrams et al , 1999 Mease et al , 2017 Mease et al , 2011 Strand et al , 2018 Abatacept Fusion protein CD80/CD86 Phase III Modest impact on psoriasis lesions while beneficial trends overall in PsA Increased risk of infection, transient headache ( 23 , 27 , 62 , 63 ) Kim et al , 2016 Peng et al , 2020 Imai et al , 2015 PD-L1-Fc Fusion protein PD-1 Preclinical Alleviated psoriatic inflammation and exhibit additive effects with or without other biologics / ( 43 , 45 , 64 ) Ellis et al , 2021 GSK2831781 mAb LAG-3 Phase I LAG-3 + and CD3 + T-cell counts reduced in peripheral blood and biopsies, reduced pro-inflammatory genes expression, disease activity improved up Headache, nasopharyngitis, back pain ( 56 ) Niwa et al , 2009 sGal-9 Stable form of Article Title: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Article Snippet: 1521-6616/$ see front matter © 200 doi:10.1016/j.clim.2009.04.012 Injection:Article Title: Role of co‑inhibitory molecules in the treatment of psoriasis (Review) Article Snippet: Author, year Name Type Targeting Status Efficacy Adverse event (Refs.) Abrams et al , 1999 Mease et al , 2017 Mease et al , 2011 Strand et al , 2018 Abatacept Fusion protein CD80/CD86 Phase III Modest impact on psoriasis lesions while beneficial trends overall in PsA Increased risk of infection, transient headache ( 23 , 27 , 62 , 63 ) Kim et al , 2016 Peng et al , 2020 Imai et al , 2015 PD-L1-Fc Fusion protein PD-1 Preclinical Alleviated psoriatic inflammation and exhibit additive effects with or without other biologics / ( 43 , 45 , 64 ) Ellis et al , 2021 GSK2831781 mAb LAG-3 Phase I LAG-3 + and CD3 + T-cell counts reduced in peripheral blood and biopsies, reduced pro-inflammatory genes expression, disease activity improved up Headache, nasopharyngitis, back pain ( 56 ) Niwa et al , 2009 sGal-9 Stable form of Article Title: Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Article Snippet: 1521-6616/$ see front matter © 200 doi:10.1016/j.clim.2009.04.012 |